Drug Approval | December 09, 2023
Vertex and CRISPR Therapeutics announce USFDA approval of Casgevy for treatment of sickle cell disease
Approximately 16,000 patients 12 years of age and older with severe sickle cell disease may now be eligible for this one-time treatment